# Evaxion Biotech (EVAX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/EVAX
## Company Profile
- Ticker: EVAX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Denmark
- Tags: Immunotherapy, Immunology
## Stock Data
- Close: 3.15 USD
- Market cap: 31275806.25 USD
- Last updated: 2026-10-05
## Business Overview
### AI-Enabled Immunotherapy Company
Evaxion Biotech uses computational models to identify antigens and design vaccines for cancer and infectious diseases. Its AI-Immunology platform analyzes immune recognition and prioritizes targets for individualized or off-the-shelf therapies.
### EVX-01 Personalized Cancer Vaccine
EVX-01 is a personalized neoantigen vaccine developed for advanced melanoma in combination with checkpoint inhibition. Each treatment is designed from the mutation profile of an individual patient's tumor.
### EVX-04 in Acute Myeloid Leukemia
EVX-04 is an off-the-shelf cancer vaccine directed at shared antigens in acute myeloid leukemia. The program is intended to bring the platform into a hematologic cancer without requiring patient-specific manufacturing.
### Infectious-Disease Programs
The infectious-disease portfolio includes EVX-B4 for Group A Streptococcus and other vaccine concepts generated through the EDEN and RAVEN platforms. These programs identify bacterial or viral antigens likely to produce protective immune responses.
### Partnered Development Model
Evaxion combines internally led programs with collaborations and licensing, including an infectious-disease program licensed to Merck. Partnerships provide validation and may generate research funding, milestones, and royalties.
### AI-Immunology Technology Stack
The PIONEER platform identifies cancer neoantigens, while EDEN and RAVEN support bacterial and viral vaccine discovery. Shared computational infrastructure allows Evaxion to generate candidates across multiple disease areas.
## Why The Stock Is Moving

As of Oct 5, 2026, EVAX closed down 1.56% at $3.15. No new same-company headline was identified in the current news window.

## Future Catalysts

- Presentation of three-year Phase 2 efficacy data for EVX-01 at ESMO 2026.
- Regulatory filing to initiate the first clinical study of EVX-04 in the second half of 2026.
- Preclinical antigen-validation data for EVX-B4 in the second half of 2026.

## Recent News
- 2022-09-21 09:45 EST — [Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy](https://biopharmsignal.com/news/EVAX/important-milestone-reached-for-evaxion-biotech-s-evx-01-personalized-cancer-the-23e72b5b) — Source: Evaxion Biotech
- 2022-09-06 11:02 EST — [Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School](https://biopharmsignal.com/news/EVAX/evaxion-announces-nih-grant-for-research-collaboration-with-umass-chan-medical-s-3645902f) — Source: Evaxion Biotech
- 2022-08-10 11:00 EST — [Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update](https://biopharmsignal.com/news/EVAX/evaxion-biotech-announces-second-quarter-2022-financial-results-and-provides-bus-7502ffcf) — Source: Evaxion Biotech
- 2022-08-02 11:00 EST — [Evaxion Biotech A/S Announces Executive Management Changes](https://biopharmsignal.com/news/EVAX/evaxion-biotech-a-s-announces-executive-management-changes-306032f9) — Source: Evaxion Biotech
- 2022-07-29 21:46 EST — [Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10](https://biopharmsignal.com/news/EVAX/evaxion-biotech-to-host-q2-2022-corporate-update-conference-call-webcast-on-augu-755bd179) — Source: Evaxion Biotech